Nanocarriers targeting the diseases of the pancreas

Demirturk N., BİLENSOY E.

EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol.170, pp.10-23, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 170
  • Publication Date: 2022
  • Doi Number: 10.1016/j.ejpb.2021.11.006
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, EMBASE, International Pharmaceutical Abstracts, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.10-23
  • Keywords: Pancreas, Nanoparticle, Drug delivery system, Pancreatic cancer, Pancreatitis, Diabetes, Exocrine pancreatic insufficiency, IRON-OXIDE NANOPARTICLES, IN-VITRO, DIABETES-MELLITUS, INSULIN THERAPY, STELLATE CELLS, DRUG-DELIVERY, CANCER, GEMCITABINE, DIAGNOSIS, EPIDEMIOLOGY
  • Hacettepe University Affiliated: Yes


Diseases of the pancreas include acute and chronic pancreatitis, exocrine pancreatic insufficiency, diabetes and pancreatic cancer. These pathologies can be difficult to treat due to the innate properties of the pancreas, its structure and localization. The need for effective targeting of the pancreatic tissue by means of nanoparticles delivering therapeutics is a major focus area covered and discussed in this review. Most common diseases of the pancreas do not have specific and direct medical treatment option, and existing treatment options are generally aimed at relieving symptoms. Diabetes has different treatment options for different subtypes based on insulin having stability problems and requiring injections reducing patient compliance. Pancreatic cancer progresses silently and can only be diagnosed in advanced stages. Therefore, survival rate of patients is very low. Gemcitabine and FOLFIRINOX treatment regimens, the most commonly used clinical standard treatments, are generally insufficient due to the chemoresistance that develops in cancer cells and also various side effects. Therefore new treatment options for pancreatic cancer are also under focus. Overcoming drug resistance and pancreatic targeting can be achieved with active and passive targeting methods, and a more effective and safer treatment regimen can be provided at lower drug doses. This review covers the current literature and clinical trials concerning pancreatic drug delivery systems in the nanoscale focusing on the challenges and opportunities provided by these smart delivery systems.